Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
recent articles
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and...
Join Proscia for a look at the future of Life Science. What’s New, What’s Next at Proscia for Life Sciences March 20 11:00 AM — 12:00 PM EDT Register View the Full Series Revolutionary advancements in technology...
Aiforia obtained the In Vitro Diagnostic Regulation (IVDR) certification and successfully launches three new CE-IVD marked AI solutions for breast and prostate cancer diagnostics Aiforia Technologies Plc, Press Release, February 20, 2025 at...
Indica Labs: Learn about the powerful new features coming soon in the 4.1 versions of HALO, HALO AI, and HALO Link! HALO®, HALO AI, and HALO Link 4.1 Sneak Peek Date: 20 March 2025 Time: 8:00 – 9:00 PDT | 11:00...
Why clearer, more actionable reports could drive wider AI adoption in diagnostics If you had asked Flora Abilova 20 years ago where she saw herself, she might have pictured a courtroom, arguing cases with the sharp precision of a seasoned...
WILMINGTON, Mass. and DUBLIN, Ireland—February 10, 2025—Charles River Laboratories International, Inc. (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus...
